# Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

> clinical trial · VERIFIED · 2026-07-01

Status: RECRUITING · Sponsor: AstraZeneca · Condition: Non-small Cell Lung Cancer (NSCLC)

- Company: AstraZeneca
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07291037

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.